Validation data for Anti-Spike-RBD hlgM (clone CR3022)

https://www.invivogen.com/sars2-spike-cr3022-mab-isotypes

For research use only

Version 20F26-NJ

Anti-Spike-RBD hlgM is a recombinant monoclonal antibody (mAb) featuring the variable region of the CR3022 human mAb that specifically targets the SARS-CoV and SARS-CoV-2 Spike receptor-binding domain (RBD) and a human lgM constant region. The binding of the antibody has been validated by ELISA, using coated Spike-RBD-His fusion peptide and a Anti-hlgM-HRP secondary antibody. Anti- β Gal hlgM has been used as a negative control (**Figure 1**).

Binding of Anti-Spike-RBD hlgM to SARS-CoV-2 RBD




Figure 1: SARS-CoV-2 Spike-RBD-His fusion peptide ($10 \, \mu g/ml$) was coated on ELISA plates overnight. A 3-fold serial dilution of the Anti-Spike-RBD hlgM (red curve) or of the Anti- β Gal hlgM control antibody (grey curve) was performed for the capture step. A HRP-labelled anti-hlgM antibody ($1/1000 \, dilution$) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

